Program
simepdekinra
Also written as “LY4100511 (DC-853)”, “LY4100511” and “LY4100511 (DC-853) Dose 1”.
Its studies are mostly in Psoriasis, led by Eli Lilly.
Furthest: phase 2, since Sep 16, 20247 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 70 open or running | phase 2since Sep 16, 2024 | Mar 8, 2024 | none ahead |
- Named in Eli Lilly’s own pipeline as
Simepdekinra
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2024First studies: 2 phase 1 studies in HealthyFirst studyNCT06311656, NCT06345794
- Jul 10, 2024Phase 1 study in HealthyNCT06503679 · 49 enrolled · United States
- Sep 12, 2024Phase 1 study in HealthyNCT06627088 · 24 enrolled · United States
- Sep 16, 2024Phase 2 study in Plaque PsoriasisNCT06602219 · 222 enrolled · United States, Canada, Czechia and more
- Apr 2, 20252 phase 1 studiesNCT06916143, NCT06937411
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06937411Healthy · United Kingdom | 1 | Completed | Oct 30, 2023 | 88 |
| NCT06916143Healthy Participants · United States | 1 | Terminated | Apr 8, 2025 | 1 |
| NCT06602219Plaque Psoriasis · United States, Canada, Czechia and more | 2 | Completed | Jul 24, 2025 | 222 |
| NCT06627088Healthy · United States | 1 | Completed | Dec 31, 2024 | 24 |
| NCT06503679Healthy · United States | 1 | Completed | Dec 31, 2024 | 49 |
| NCT06345794Healthy · United States | 1 | Completed | Jun 18, 2024 | 50 |
| NCT06311656Healthy · United States | 1 | Completed | Oct 4, 2024 | 69 |
How it is read
Names in the registry
- “LY4100511 (DC-853)”, 5 entries
- “LY4100511”, 3 entries
- “LY4100511 (DC-853) Dose 1”, 1 entry
- “LY4100511 (DC-853) Dose 2”, 1 entry
- “LY4100511 (DC-853) Dose 3”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.